EP1957113A4 - Polymerteilchen zur ausgabe von makromolekülen und anwendungsverfahren dafür - Google Patents

Polymerteilchen zur ausgabe von makromolekülen und anwendungsverfahren dafür

Info

Publication number
EP1957113A4
EP1957113A4 EP06851769A EP06851769A EP1957113A4 EP 1957113 A4 EP1957113 A4 EP 1957113A4 EP 06851769 A EP06851769 A EP 06851769A EP 06851769 A EP06851769 A EP 06851769A EP 1957113 A4 EP1957113 A4 EP 1957113A4
Authority
EP
European Patent Office
Prior art keywords
macromolecules
administration
methods
polymeric particles
polymeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06851769A
Other languages
English (en)
French (fr)
Other versions
EP1957113A2 (de
Inventor
Zaza D Gomurashvili
Geoffrey C Landis
Hong Li
William D Turnell
Kristin Defife
Vassil P Vassilev
Yumin Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivas LLC
Original Assignee
Medivas LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivas LLC filed Critical Medivas LLC
Publication of EP1957113A2 publication Critical patent/EP1957113A2/de
Publication of EP1957113A4 publication Critical patent/EP1957113A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
    • C08L77/12—Polyester-amides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP06851769A 2005-11-21 2006-11-21 Polymerteilchen zur ausgabe von makromolekülen und anwendungsverfahren dafür Withdrawn EP1957113A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73876905P 2005-11-21 2005-11-21
US79606706P 2006-04-27 2006-04-27
PCT/US2006/045268 WO2008048298A2 (en) 2005-11-21 2006-11-21 Polymer particles for delivery of macromolecules and methods of use

Publications (2)

Publication Number Publication Date
EP1957113A2 EP1957113A2 (de) 2008-08-20
EP1957113A4 true EP1957113A4 (de) 2011-11-09

Family

ID=39314537

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06851769A Withdrawn EP1957113A4 (de) 2005-11-21 2006-11-21 Polymerteilchen zur ausgabe von makromolekülen und anwendungsverfahren dafür

Country Status (5)

Country Link
US (1) US20070134332A1 (de)
EP (1) EP1957113A4 (de)
JP (1) JP2009518289A (de)
CA (1) CA2670355A1 (de)
WO (1) WO2008048298A2 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286064A1 (en) * 2000-08-30 2006-12-21 Medivas, Llc Therapeutic polymers and methods
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
AU2006279304A1 (en) * 2005-08-19 2007-02-22 Endocyte, Inc. Multi-drug ligand conjugates
JP5192384B2 (ja) 2005-09-22 2013-05-08 メディバス エルエルシー ビス−（α−アミノ）−ジオール−ジエステル含有ポリ（エステルアミド）およびポリ（エステルウレタン）組成物および使用の方法
CA2623239C (en) * 2005-09-22 2016-07-12 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
US8765164B2 (en) * 2005-10-21 2014-07-01 Kenneth W. Carpenter Poly(ester urea) polymers and methods of use
JP2009524584A (ja) * 2005-12-07 2009-07-02 メディバス エルエルシー ポリマー−生物製剤送達組成物を構築するための方法
WO2007083984A1 (en) * 2006-01-23 2007-07-26 Gwangju Institute Of Science And Technology Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same
CA2649672C (en) * 2006-05-02 2015-07-07 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
US20070282011A1 (en) * 2006-05-09 2007-12-06 Medivas, Llc Biodegradable water soluble polymers
WO2008040488A1 (en) * 2006-10-04 2008-04-10 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
US7956345B2 (en) * 2007-01-24 2011-06-07 Stmicroelectronics Asia Pacific Pte. Ltd. CNT devices, low-temperature fabrication of CNT and CNT photo-resists
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
JP2010533548A (ja) * 2007-07-17 2010-10-28 メディバス エルエルシー 生体吸収性エラストマー動脈支持装置および使用方法
US20090029937A1 (en) * 2007-07-24 2009-01-29 Cornell University Biodegradable cationic polymer gene transfer compositions and methods of use
EP4464384A3 (de) 2007-08-17 2025-01-08 Purdue Research Foundation Psma-bindungsliganden-linker-konjugate und anwendungsverfahren
US7923486B2 (en) * 2007-10-04 2011-04-12 Board Of Regents, The University Of Texas System Bio-polymer and scaffold-sheet method for tissue engineering
US20110027379A1 (en) * 2007-12-06 2011-02-03 Cornell University Oligo-Ethylene Glycol-Based Polymer Compositions and Methods of Use
WO2009073814A2 (en) * 2007-12-06 2009-06-11 Medivas, Llc Oligo-ethylene glycol-based polymer compositions and methods of use
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
FR2930176B1 (fr) * 2008-04-18 2011-03-18 Univ Claude Bernard Lyon Nouveau procede de fabrication de nanocapsules, en l'absence de solvant organique, et nanocapsules ainsi obtenues
CA2723721A1 (en) * 2008-05-07 2009-11-12 Medivas, Llc Biodegradable metal-chelating polymers and vaccines
WO2010045241A1 (en) * 2008-10-15 2010-04-22 Medivas, Llc Biodegradable proline-based polymers
WO2010045598A2 (en) * 2008-10-17 2010-04-22 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US20100310726A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Novel Preparation of an Enteric Release System
US8859003B2 (en) * 2009-06-05 2014-10-14 Intercontinental Great Brands Llc Preparation of an enteric release system
US9968564B2 (en) * 2009-06-05 2018-05-15 Intercontinental Great Brands Llc Delivery of functional compounds
US20100307542A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Method of Reducing Surface Oil on Encapsulated Material
CA2767342C (en) 2009-07-09 2018-05-01 Oshadi Drug Administration Ltd. Matrix carrier compositions, methods and uses
WO2011017835A1 (en) 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10421843B2 (en) 2010-03-09 2019-09-24 Cornell University Poly(ester amide) macromers and polymers thereof
WO2012003003A2 (en) 2010-07-01 2012-01-05 Covaris, Inc. Compositions and methods for preparing nanoformulations and systems for nano-delivery using focused acoustics
DE102011018499A1 (de) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US9963549B2 (en) * 2011-06-23 2018-05-08 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US8859004B2 (en) * 2011-08-04 2014-10-14 Nano And Advanced Materials Institute Limited pH-sensitive nanoparticles for oral insulin delivery
US20150038415A1 (en) * 2011-12-16 2015-02-05 Dsm Ip Assets B.V. Process for the manufacturing of a drug delivery system based on a polymer comprising a dispersed bioactive agent
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US10357450B2 (en) 2012-04-06 2019-07-23 Children's Medical Center Corporation Process for forming microbubbles with high oxygen content and uses thereof
CA2881729C (en) * 2012-10-02 2021-05-04 Dsm Ip Assets B.V. Drug delivery composition comprising proteins and biodegradable polyesteramides
EP2908818A4 (de) 2012-10-16 2016-07-13 Endocyte Inc Wirkstofffreisetzungskonjugate mit unnatürlichen aminosäuren und verfahren zur verwendung
CA2888840C (en) * 2012-10-23 2021-06-22 Dsm Ip Assets B.V. Process for the manufacturing of a multilayer drug delivery construct
EP3702394B1 (de) * 2012-10-24 2023-11-22 DSM IP Assets B.V. Fasern mit polyesteramidcopolymeren zur wirkstofffreisetzung
US10538864B2 (en) 2012-10-24 2020-01-21 Dsm Ip Assets, B.V. Fibers comprising polyesteramide copolymers for drug delivery
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
US20150328374A1 (en) * 2012-12-20 2015-11-19 Dsm Ip Assets B.V. Coating comprising polyesteramide copolymers for drug delivery
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
WO2014144364A1 (en) 2013-03-15 2014-09-18 Children's Medical Center Corporation Gas-filled stabilized particles and methods of use
US9840583B2 (en) 2013-07-09 2017-12-12 Board Of Regents, The University Of Texas System Fluorescent polymers and applications thereof
EP3052471B1 (de) 2013-09-30 2023-06-21 The University of Akron Verfahren zur funktionalisierung von poly(esterharnstoffen) nach der herstellung
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
EP3177668B1 (de) * 2014-08-08 2020-11-18 DSM IP Assets B.V. Reduktionsempfindliche biologisch abbaubare polyesteramide
EP3177669B1 (de) * 2014-08-08 2021-03-17 DSM IP Assets B.V. Amphiphile blockcopolymere mit reduktionsempfindlichen, biologisch abbaubaren polyesteramiden
EP3233067B1 (de) 2014-12-18 2019-11-06 DSM IP Assets B.V. Arzneimittelabgabesystem zur abgabe von säureempfindlichen arzneimitteln
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2017139212A1 (en) * 2016-02-08 2017-08-17 Cyta Therapeutics, Inc. Particle delivery of rapamycin to the liver
JPWO2018025699A1 (ja) * 2016-08-02 2019-05-30 日本化薬株式会社 アクティブターゲティング型高分子誘導体、その高分子誘導体を含む組成物、及びそれらの用途
US11147890B2 (en) 2017-02-28 2021-10-19 Children's Medical Center Corporation Stimuli-responsive particles encapsulating a gas and methods of use
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
CN109734901B (zh) * 2018-12-21 2021-05-04 东华大学 一种多肽基聚酯氨型纳米粒子及其制备和应用
CN109734900B (zh) * 2018-12-21 2021-05-04 东华大学 一种可酶降解型多肽基聚酯氨及其制备方法和应用
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
US12577398B2 (en) 2019-11-12 2026-03-17 Dsm Ip Assets B.V. Polyesteramide copolymers possessing high glass transition temperatures
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
EP4472686A1 (de) * 2022-02-01 2024-12-11 DSM IP Assets B.V. Abbaubare partikel mit hohen rapamycin-anteilen
US20240207144A1 (en) * 2022-12-19 2024-06-27 Leading Edge Innovations, LLC Oil-in-water despersions of hydrophobic agents and polymer or copolymer fragments, or combinations thereof, and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20040063606A1 (en) * 2001-08-30 2004-04-01 Chih-Chang Chu Elastomeric functional biodegradable copolyester amides and copolyester urethanes
WO2004039944A2 (en) * 2002-05-15 2004-05-13 Rutgers, The State University Tri-block polymers for nanosphere-based drug or gene delivery
US20060177416A1 (en) * 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
WO2006083874A2 (en) * 2005-02-01 2006-08-10 Medivas, Llc. Vaccine delivery compositions and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19500756A1 (de) * 1995-01-13 1996-07-18 Basf Ag Biologisch abbaubare Polymere, Verfahren zu deren Herstellung sowie deren Verwendung zur Herstellung bioabbaubarer Formkörper
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
US5916585A (en) * 1996-06-03 1999-06-29 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto biodegradable polymers
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US20030180368A1 (en) * 1998-03-14 2003-09-25 Cenes Drug Delivery Limited Production of microparticles
US6503538B1 (en) * 2000-08-30 2003-01-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
JP2006503004A (ja) * 2002-07-31 2006-01-26 アルザ・コーポレーション 射出可能なデポ組成物及びその使用
NZ554885A (en) * 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
US20060188486A1 (en) * 2003-10-14 2006-08-24 Medivas, Llc Wound care polymer compositions and methods for use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20040063606A1 (en) * 2001-08-30 2004-04-01 Chih-Chang Chu Elastomeric functional biodegradable copolyester amides and copolyester urethanes
WO2004039944A2 (en) * 2002-05-15 2004-05-13 Rutgers, The State University Tri-block polymers for nanosphere-based drug or gene delivery
US20060177416A1 (en) * 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
WO2006083874A2 (en) * 2005-02-01 2006-08-10 Medivas, Llc. Vaccine delivery compositions and methods of use

Also Published As

Publication number Publication date
WO2008048298A2 (en) 2008-04-24
WO2008048298A3 (en) 2008-10-23
JP2009518289A (ja) 2009-05-07
EP1957113A2 (de) 2008-08-20
US20070134332A1 (en) 2007-06-14
CA2670355A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
EP1957113A4 (de) Polymerteilchen zur ausgabe von makromolekülen und anwendungsverfahren dafür
EP1933881A4 (de) Feste polymer-abgabezusammensetzungen und anwendungsverfahren dafür
EP2076246A4 (de) Formierung medizinisch nützlicher gele mit mikroporösen partikeln und verwendungsverfahren dafür
FR20C1033I2 (fr) Anticorps anti-cd79b, immuno-conjugues et procedes d'utilisation
EP1881821A4 (de) Cyclooxygenase-hemmer und calciumkanal-antagonistenzusammensetzungen sowie verwendung für urologische verfahren
EP2259782A4 (de) Pharmazeutische formulierungen von resveratrol und verfahren zur ihrer anwendung bei der behandlung von zellerkrankungen
EP1879626A4 (de) Amphiphile polymere und verfahren zur verwendung davon
EP2117470A4 (de) Bandscheibenimplantatvorrichtung und einsatzverfahren dafür
EP1877090A4 (de) Trimeres ox40-immunglobulin-fusionsprotein und verwendungsverfahren
EP1831207A4 (de) Aminopyrimidinverbindungen und anwendungsverfahren
EP2077776A4 (de) Gerät und verfahren zur verwendung von expandierbaren elementen in chirurgischen anwendungen
EP1855833A4 (de) Plasmata und verfahren zu ihrer verwendung
EP2171460A4 (de) Materialien zur erfassung von polynukleotiden und verfahren zu ihrer verwendung
EP1817008A4 (de) Stabilisierte hme-zusammensetzung mit kleinen wirkstoffpartikeln
EP2334279A4 (de) Stickoxid freisetzende partikel für mundpflegeanwendungen
EP2209420A4 (de) Partikel für bildgebung
EP1989567A4 (de) Verfahren und system zur einschränkung der verwendung von positionsbestimmungsgeräten auf bestimmte regionen
EP1608318A4 (de) Cxcr4 antagonisten und anwendungsverfahren
EP1959966A4 (de) Ganaxolon-formulierungen und verfahren zu ihrer herstellung und verwendung
EP1718282A4 (de) Verfahren und zusammensetzungen für die bilddarstellung
EP2084275A4 (de) Polypeptidliganden zur abzielung auf knorpel und verfahren zur verwendung davon
EP1838331A4 (de) Antimikrobielle peptide und anwendungsverfahren
NO20053987L (no) Flytende farmasoytiske palonosetronformuleringer
EP1971600A4 (de) Isoxazolderivate und deren verwendung
EP1933884A4 (de) Abbildungswirkstoffe und verfahren zu ihrer verwendung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080623

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YUAN, YUMIN

Inventor name: VASSILEV, VASSIL, P.

Inventor name: DEFIFE, KRISTIN

Inventor name: TURNELL, WILLIAM, D.

Inventor name: LI, HONG

Inventor name: LANDIS, GEOFFREY C.

Inventor name: GOMURASHVILI, ZAZA D.

R17D Deferred search report published (corrected)

Effective date: 20081023

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101AFI20081222BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20111010

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/28 20060101ALI20111004BHEP

Ipc: A61K 9/107 20060101ALI20111004BHEP

Ipc: A61K 9/16 20060101ALI20111004BHEP

Ipc: A61K 9/50 20060101ALI20111004BHEP

Ipc: A61K 9/51 20060101ALI20111004BHEP

Ipc: C12N 15/88 20060101ALI20111004BHEP

Ipc: C07K 16/28 20060101ALI20111004BHEP

Ipc: A61K 47/48 20060101ALI20111004BHEP

Ipc: A61K 47/34 20060101ALI20111004BHEP

Ipc: C08L 75/02 20060101ALI20111004BHEP

Ipc: C08L 75/06 20060101ALI20111004BHEP

Ipc: C08L 75/04 20060101ALI20111004BHEP

Ipc: C08L 77/12 20060101ALI20111004BHEP

Ipc: C08G 69/44 20060101ALI20111004BHEP

Ipc: C08G 18/10 20060101ALI20111004BHEP

Ipc: A61L 31/00 20060101ALI20111004BHEP

Ipc: A61F 2/00 20060101ALI20111004BHEP

Ipc: C08L 77/00 20060101AFI20111004BHEP

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120508